Immunogenicity

Immunogenicity is the intrinsic propensity of a therapeutic peptide or biological product to trigger an unwanted immune reaction in an administered host, resulting in the production of Anti-Drug Antibodies (ADAs) or cell-mediated hypersensitivity. Immunogenicity can lead to altered clearance kinetics, loss of clinical efficacy (neutralizing antibodies), or severe autoimmune cross-reactivity with endogenous human hormones.

Synthetic peptide impurities, sequence modifications, and molecular aggregation drastically elevate immunogenicity. During regulatory review, health authorities mandate extensive clinical immunogenicity assays to ensure that therapeutic peptides do not trigger neutralizing cross-reactive antibodies.

Antibodies against a therapeutic peptide or protein can be harmless, can blunt the drug’s effect, or, rarely, can cross-react with the body’s own hormone. The best-known warning came in 2002, when clinicians in France described 13 patients who developed pure red-cell aplasia while treated with recombinant erythropoietin. All had neutralising antibodies that blocked red blood cell production, showing that a medicine built on a natural human hormone can still turn the immune system against it.

Immunogenicity depends on manufacturing as well as the active ingredient. Synthesis byproducts with inserted, missing or modified amino acids may create new targets for immune cells. FDA’s 2021 guidance on generic synthetic peptides asks applicants to characterise and limit such impurities and to assess new ones for immunogenicity risk. Peptides sold outside the regulated supply chain skip that scrutiny entirely, so their impurity profile and immune risk are unknown.

Immune reactions can take weeks or months to appear and may be uncommon, so they are usually detected through systematic antibody testing in clinical trials and safety monitoring after approval. Informal user reports cannot do this job. A claim that a research peptide has “no reported side effects” says little about immunogenicity, because nobody has looked in a structured way.

“Peptides are too small to trigger an immune response”

Short peptides are generally less immunogenic than large proteins, but they are not immune-proof. FDA-affiliated laboratory studies have measured T-cell responses to salmon calcitonin and to some of its impurities, and found several teriparatide impurities more immunogenic than teriparatide itself in laboratory assays. Size lowers risk; it does not remove it.

“Anti-drug antibodies always mean the drug has stopped working”

Many anti-drug antibodies bind a drug without affecting how it works and cause no symptoms. Neutralising antibodies can reduce effectiveness, and in rare cases antibodies cross-react with a natural hormone and cause harm. FDA asks for immunogenicity to be assessed case by case using a risk-based approach, because the consequences differ widely between products.

“A body-identical sequence cannot be immunogenic”

Recombinant erythropoietin has the human amino acid sequence, yet it was linked to neutralising antibodies and pure red-cell aplasia. Product-related factors such as impurities, aggregation and formulation influence immune responses, which is why regulators assess the finished product rather than assuming a natural sequence is automatically safe.

What are anti-drug antibodies?

Anti-drug antibodies (ADAs) are antibodies the immune system makes against a medicine, usually a protein or peptide. Some simply bind the drug, some speed its removal from the body, and neutralising antibodies block its activity. Clinical trials of biological and peptide drugs test for ADAs so that their frequency and effects can be described before and after approval.

Why does peptide purity affect immunogenicity?

Impurities from peptide synthesis can differ from the intended molecule by an extra, missing or modified amino acid. These altered sequences may contain new fragments that immune cells recognise as foreign. That is why FDA guidance for generic synthetic peptides sets limits on impurities and asks for new impurities above a threshold to be assessed for immunogenicity risk.

How is immunogenicity tested?

In clinical trials, blood samples are checked for antibodies against the drug, and positive samples are tested further to see whether the antibodies neutralise it. For generic synthetic peptides, FDA-linked research has also used computer prediction tools, laboratory HLA-binding assays and human immune-cell (T-cell) assays to compare impurities with the reference drug.

Have research-chemical peptides been tested for immunogenicity?

Peptides sold as research chemicals have not gone through the regulatory immunogenicity assessment that approved drugs and generics face. Their impurity profiles vary between batches and sellers, and no structured antibody monitoring exists for people using them. Their immune risk is therefore essentially uncharacterised, rather than shown to be low.